Literature DB >> 31339561

Prognostic factors and patterns of failure after surgery for T4 rectal cancer in the beyond total mesorectal excision era.

O Peacock1, P S Waters1, M Bressel2, A C Lynch1, C Wakeman3, T Eglinton3, C E Koh4, P J Lee4, K K Austin4, S K Warrier1, M J Solomon4,5, F A Frizelle3, A G Heriot1.   

Abstract

BACKGROUND: Despite advances in the rates of total mesorectal excision (TME) for rectal cancer surgery, decreased local recurrence rates and increased 5-year survival, there still exists large variation in the quality of treatment received. Up to 30 per cent of rectal cancers are locally advanced at presentation and approximately 5-10 per cent still breach the mesorectal plane and invade adjacent structures despite neoadjuvant therapy. With the evolution of extended resections for rectal cancers beyond the TME plane, proponents advocate that these resections should be performed only in specialist centres. The aim was to assess the prognostic factors and patterns of failure after beyond TME surgery for T4 rectal cancers.
METHODS: Data were collected from prospective databases at three high-volume institutions specializing in beyond TME surgery for T4 rectal cancers between 1990 and 2013. The primary outcome measures were overall survival, local recurrence and patterns of first failure.
RESULTS: Three hundred and sixty patients were identified. The negative resection margin (R0) rate was 82·8 per cent (298 patients) and the local recurrence rate was 12·5 per cent (45 patients). The type of surgical procedure (Hartmann's: hazard ratio (HR) 4·49, 95 per cent c.i. 1·99 to 10·14; P = 0·002) and lymphovascular invasion (HR 2·02, 1·08 to 3·77; P = 0·032) were independent predictors of local recurrence. The 5-year overall survival rate for all patients was 61 (95 per cent c.i. 55 to 67) per cent. The 5-year cumulative incidence of first failure was 8 per cent for local recurrence, 6 per cent for local and distant disease, and 18 per cent for distant disease.
CONCLUSION: This study has demonstrated that a coordinated approach in specialist centres for beyond TME surgery can offer good oncological and long-term survival in patients with T4 rectal cancers.
© 2019 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Year:  2019        PMID: 31339561     DOI: 10.1002/bjs.11242

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  4 in total

1.  Therapeutic effects and limitations of chemoradiotherapy in advanced lower rectal cancer focusing on T4b.

Authors:  Kosuke Ozaki; Kazushige Kawai; Hiroaki Nozawa; Kazuhito Sasaki; Koji Murono; Shigenobu Emoto; Yuuki Iida; Hiroaki Ishii; Yuichiro Yokoyama; Hiroyuki Anzai; Hirofumi Sonoda; Kenichi Sugihara; Soichiro Ishihara
Journal:  Int J Colorectal Dis       Date:  2021-05-03       Impact factor: 2.571

2.  Complications and 5-year survival after radical resections which include urological organs for locally advanced and recurrent pelvic malignancies: analysis of 646 consecutive cases.

Authors:  Oliver Peacock; Peadar S Waters; Joseph C Kong; Satish K Warrier; Chris Wakeman; Tim Eglinton; Declan G Murphy; Alexander G Heriot; Frank A Frizelle; Jacob J McCormick
Journal:  Tech Coloproctol       Date:  2020-01-06       Impact factor: 3.781

3.  A matched cohort study of the failure pattern after laparoscopic and open gastrectomy for locally advanced gastric cancer: does the operative approach matter?

Authors:  Jun Lu; Dong Wu; Bin-Bin Xu; Zhen Xue; Hua-Long Zheng; Jian-Wei Xie; Jia-Bin Wang; Jian-Xian Lin; Ping Li; Chao-Hui Zheng; Chang-Ming Huang
Journal:  Surg Endosc       Date:  2021-02-16       Impact factor: 4.584

4.  Association of tumor size in pathological T4 colorectal cancer with desmoplastic reaction and prognosis.

Authors:  Takuya Shiraishi; Hiroomi Ogawa; Ayaka Katayama; Katsuya Osone; Takuhisa Okada; Yasuaki Enokida; Tetsunari Oyama; Makoto Sohda; Ken Shirabe; Hiroshi Saeki
Journal:  Ann Gastroenterol Surg       Date:  2022-03-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.